PUBLICATIONS
1. Shore ND, Fernandez CA, Shuber AP. Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence. Research and Reports in Urology 2012 Oct; Online. Abstract
2. Karnes RJ, Fernandez CA, Shuber AP. A Noninvasive Multianalyte Urine-Based Diagnostic Assay for Urothelial Cancer of the Bladder in the Evaluation of Hematuria. Mayo Clin Proc 2012 Aug; Online. Abstract
3. Millholland JM, Li S, Fernandez CA, Shuber AP. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Research and Reports in Urology 2012 Jun; 2012(4) 33-40. Abstract
4. Fernandez CA, Millholland JM, Zwarthoff EC, Feldman AS, Karnes RJ, Shuber AP. A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients. Research and Reports in Urology 2012 Mar; 2012(4) 17-26. Abstract
5. Fernandez CA, Wszolek MF, Loughlin, KR, Libertino JA, Summerhayes IC, Shuber AP. A Novel approach to using matrix metalloproteinases for bladder cancer. J Urol 2009 Nov; 182(5) 2188-94. Abstract
PRESENTATIONS
1. Combining next-gen sequencing of TP53 and FGFR3 for detecting bladder cancer-related mutations.
John M. Millholland, Maria F. Campo, Cecilia A. Fernándezand Anthony P. Shuber. Presented at the ASCO GU Annual Meeting 2013. Poster
2. Next‐Gen Sequencing Improves FGFR3 Mutation Detection in the Urine of Bladder Cancer Patients.
John M. Millholland, Shuqiang Li, Cecilia A. Fernándezand Anthony P. Shuber. Presented at the AACR Annual Meeting 2012. Poster
3. Multiplexing Protein and DNA Biomarkers on a Single Analytical Platform.
Shuqiang Li, Maria F. Campo, Cecilia A. Fernández and Anthony P. Shuber. Presented at the AACR Annual Meeting 2012. Poster
4. Next-Gen Deep Sequencing Improves FGFR3 Mutation Detection in the Urine of Bladder Cancer Patients.
John M. Millholland, Shuqiang Li, Cecilia A. Fernández and Anthony P. Shuber. Presented at the ASCO GU Meeting 2012. Poster
5. Development of a Non-Invasive, Multi-Analyte Assay for the Triage of Patients Presenting with Hematuria.
Cecilia A. Fernández, John M. Millholland, Ellen C. Zwarthoff, Kevin R. Loughlin, Adam Feldman, R. Jeffrey Karnes and Anthony P. Shuber. Presented at the AACR Annual Meeting 2011. Poster
6. Development of a real-time multiplex PCR assay for the detection of FGFR3 mutations in urine and tissue.
John M. Millholland, Sheryl G. Patel, Stephen Lyle, Chanho Park, Cecilia A. Fernández, and Anthony P. Shuber.Presented at the AACR Annual Meeting 2011. Poster
7. Improved PCR Amplification of DNA Biomarkers with the Use of Chimeric Oligonucleotides.
John M. Millholland, Sheryl G. Patel, Shuqiang Li, Lei Li, Lydia Anderson, Cecilia A. Fernández, and Anthony P. Shuber. Presented at the AACR Annual Meeting 2011. Poster
8. Devlopment of a real-time multiplex PCR assay for the detection of FGFR3 mutations in urine and tissue.
John Millholland, Sheryl Patel, Stephen Lyle, Chando Park, Cecilia A. Fernández, and Anthony P. Shuber.Presented at the Genitourinary Cancer Symposium, 2011. Poster
9. Multi-Analyte Diagnostic Readout (MADR): Combining Protein and DNA Markers to Maximize Clinical Performance.
Cecilia A. Fernández, John Millholland, Ian C. Summerhayes, John A. Libertino, R. Jeffrey Karnes and Anthony P. Shuber.Presented at the Genitourinary Cancer Symposium, 2010. Poster
10. Multi-Analyte Diagnostic Readout (MADR): Combining Protein and DNA Markers to Maximize Clinical Performance.
Cecilia A. Fernández, John Millholland, Ian C. Summerhayes, John A. Libertino, R. Jeffrey Karnes and Anthony P. Shuber.Presented at the 10th Annual Meeting of the Society of Urologic Oncology, 2009. Poster
11. Development of a Novel Bladder Cancer Intervention Diagnostic Triage Assay Using Urinary Matrix Metalloproteinases (MMPs) as Clinical Biomarkers.
Cecilia A. Fernández, Matthew F. Wszolek, Autumn R. Duchesne, Ying Feng, Sheryl Patel, Lauren Robison, John A. Libertino, Ian C. Summerhayes and Anthony P. Shuber.Presented at the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, 2008. Poster
12. Development of a Diagnostic Test for Monitoring Bladder Cancer Recurrence Using Urinary Matrix Metalloproteinases (MMPs) as Clinical Biomarkers.
C. A. Fernández, Y. Feng, S. Patel, L. Robison and A. P. Shuber.Presented at the CHI Biomarker Discovery Summit, 2007. Poster
13. Sample Collection Impacts the Performance of Urinary Matrix Metalloproteinases (MMPs) as Diagnostic Biomarkers for Bladder Cancer Recurrence.
C. A. Fernández, S. Patel, L. Robison and A. P. Shuber.Presented at the GTCbio Rediscovering Biomarkers Meeting, 2007. Poster
14. Development of a Diagnostic Test for Monitoring Bladder Cancer Recurrence Using Urinary Matrix Metalloproteinases (MMPs) as Clinical Biomarkers.
Cecilia A. Fernández, Ying Feng, Sheryl Patel, Lauren Robison and Anthony P. Shuber.Presented at the AACR: Frontiers in Cancer Prevention Research Sixth Annual AACR International Conference, 2007. Poster
